Paik J (2022) Nivolumab plus Relatlimab: first approval. Drugs 82:925–931

Article  PubMed  Google Scholar 

Vaddepally RK, Kharel P, Pandey R et al (2020) Review of indications of fda-approved immune checkpoint inhibitors per nccn guidelines with the level of evidence. Cancers (Basel) 12

Powles T (2021) clinicalguidelines@esmo.org EGCEa. Recent eupdate to the esmo clinical practice guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: renal cell carcinoma: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 32:422–423

Article  PubMed  Google Scholar 

Xu C, Chen YP, Du XJ et al (2018) Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ 363:k4226

Article  PubMed  PubMed Central  Google Scholar 

Johnson DB, Balko JM, Compton ML et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375:1749–1755

Article  PubMed  PubMed Central  Google Scholar 

Suzuki S, Ishikawa N, Konoeda F et al (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89:1127–1134

Article  PubMed  Google Scholar 

Mahmood SS, Fradley MG, Cohen JV et al (2018) Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71:1755–1764

Article  PubMed  PubMed Central  Google Scholar 

Kalbasi A, Ribas A (2020) Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol 20:25–39

Article  PubMed  Google Scholar 

Fung G, Luo H, Qiu Y et al (2016) Myocarditis Circ Res 118:496–514

Article  PubMed  Google Scholar 

Thompson JA, Schneider BJ, Brahmer J et al (2020) Nccn guidelines insights: management of immunotherapy-related toxicities, version 1.2020. J Natl Compr Canc Netw 18:230–241

Article  PubMed  Google Scholar 

Ganatra S, Neilan TG (2018) Immune checkpoint inhibitor-associated myocarditis. Oncologist 23:879–886

Article  PubMed  PubMed Central  Google Scholar 

Varricchi G, Galdiero MR, Marone G et al (2017) Cardiotoxicity of immune checkpoint inhibitors. ESMO Open 2:e000247

Article  PubMed  PubMed Central  Google Scholar 

Salem JE, Manouchehri A, Moey M et al (2018) Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 19:1579–1589

Article  PubMed  PubMed Central  Google Scholar 

Moslehi JJ, Salem JE, Sosman JA et al (2018) Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391:933

Article  PubMed  PubMed Central  Google Scholar 

Poto R, Marone G, Pirozzi F et al (2021) How can we manage the cardiac toxicity of immune checkpoint inhibitors? Expert Opin Drug Saf 20:685–694

Article  PubMed  Google Scholar 

Zito C, Manganaro R, Cusma Piccione M et al (2021) Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the working group on drug cardiotoxicity and cardioprotection, Italian society of cardiology (sic). Eur Heart J Cardiovasc Imaging 22:406–415

Article  PubMed  Google Scholar 

Fedele C, Riccio G, Coppola C et al (2012) Comparison of preclinical cardiotoxic effects of different erbb2 inhibitors. Breast Cancer Res Treat 133:511–521

Article  PubMed  Google Scholar 

Mercurio V, Cuomo A, Della Pepa R et al (2019) What is the cardiac impact of chemotherapy and subsequent radiotherapy in lymphoma patients? Antioxid Redox Signal 31:1166–1174

Article  PubMed  Google Scholar 

Awadalla M, Golden DLA, Mahmood SS et al (2019) Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. J Immunother Cancer 7:53

Article  PubMed  PubMed Central  Google Scholar 

Sury K, Perazella MA, Shirali AC (2018) Cardiorenal complications of immune checkpoint inhibitors. Nat Rev Nephrol 14:571–588

Article  PubMed  Google Scholar 

Darnell EP, Mooradian MJ, Baruch EN et al (2020) Immune-related adverse events (iraes): diagnosis, management, and clinical pearls. Curr Oncol Rep 22:39

Article  PubMed  Google Scholar 

Kimura T, Fukushima S, Miyashita A et al (2016) Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci 107:1055–1058

Article  PubMed  PubMed Central  Google Scholar 

Saishu Y, Yoshida T, Seino Y et al (2022) Nivolumab-related myasthenia gravis with myositis requiring prolonged mechanical ventilation: a case report. J Med Case Rep 16:61

Article  PubMed  PubMed Central  Google Scholar 

Caforio ALP, Malipiero G, Marcolongo R et al (2017) Myocarditis: a clinical overview. Curr Cardiol Rep 19:63

Article  PubMed  Google Scholar 

Atallah-Yunes SA, Kadado AJ, Kaufman GP et al (2019) Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases. J Cancer Res Clin Oncol 145:1527–1557

Article  PubMed  Google Scholar 

Kindermann I, Barth C, Mahfoud F et al (2012) Update on myocarditis. J Am Coll Cardiol 59:779–792

Article  PubMed  Google Scholar 

Monge C, Maeng H, Brofferio A et al (2018) Myocarditis in a patient treated with nivolumab and prostvac: a case report. J Immunother Cancer 6:150

Article  PubMed  PubMed Central  Google Scholar 

Zhou YW, Zhu YJ, Wang MN et al (2019) Immune checkpoint inhibitor-associated cardiotoxicity: current understanding on its mechanism, diagnosis and management. Front Pharmacol 10:1350

Article  PubMed  PubMed Central  Google Scholar 

Nishimura H, Okazaki T, Tanaka Y et al (2001) Autoimmune dilated cardiomyopathy in pd-1 receptor-deficient mice. Science 291:319–322

Article  PubMed  Google Scholar 

Lucas JA, Menke J, Rabacal WA et al (2008) Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in mrl mice. J Immunol 181:2513–2521

Article  PubMed  Google Scholar 

Wang J, Okazaki IM, Yoshida T et al (2010) Pd-1 deficiency results in the development of fatal myocarditis in mrl mice. Int Immunol 22:443–452

Article  PubMed  Google Scholar 

Rikhi R, Karnuta J, Hussain M et al (2021) Immune checkpoint inhibitors mediated lymphocytic and giant cell myocarditis: uncovering etiological mechanisms. Front Cardiovasc Med 8:721333

Article  PubMed  PubMed Central  Google Scholar 

Reuben A, Petaccia de Macedo M, McQuade J et al (2017) Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. Oncoimmunology 6:e1361097

Article  PubMed  PubMed Central  Google Scholar 

Tay RY, Blackley E, McLean C et al (2017) Successful use of equine anti-thymocyte globulin (atgam) for fulminant myocarditis secondary to nivolumab therapy. Br J Cancer 117:921–924

Article  PubMed  PubMed Central  Google Scholar 

Yamaguchi S, Morimoto R, Okumura T et al (2018) Late-onset fulminant myocarditis with immune checkpoint inhibitor nivolumab. Can J Cardiol 34:812. e811-812 e813

Article  Google Scholar 

Rubio-Infante N, Ramírez-Flores YA, Castillo EC et al (2022) A systematic review of the mechanisms involved in Immune checkpoint inhibitors Cardiotoxicity and challenges to improve clinical safety. Front Cell Dev Biol 10:851032

Article  PubMed  PubMed Central  Google Scholar 

Haanen J, Obeid M, Spain L et al (2022) Management of toxicities from immunotherapy: Esmo clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 33:1217–1238

Article  PubMed  Google Scholar 

Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 36:1714–1768

Article  PubMed  Google Scholar 

Kwon HJ, Cote TR, Cuffe MS et al (2003) Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 138:807–811

Article  PubMed  Google Scholar